NDA 203284 · Horizon Therap US
Ravicti
Glycerol Phenylbutyrate · Oral
OrphanLast checked: Nov 20, 2026Latest source record: Sep 3, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Feb 1, 2013
Approved uses
5
Original approval plus efficacy supplements
Registered trials
21
4 Phase 3, 3 recruiting
FAERS reports
1,392
843 serious, 66 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 29, 2025.
RAVICTI is indicated for use as a nitrogen-binding agent for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements). Limitations of Use: RAVICTI is not indicated for the treatment of acute hyperammonemia in patients with UCDs because more rapidly acting interventions are essential to reduce plasma ammonia levels. The safety and efficacy of RAVICTI for the treatment of N- acetylglutamate synthase (NAGS) deficiency has not been established. RAVICTI is a nitrogen-binding agent indicated for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements. ( 1 ) Limitations of Use : RAVICTI is not indicated for treatment of acute hyperammonemia in patients with UCDs. ( 1 ) Safety and efficacy for treatment of N-acetylglutamate synthase (NAGS) deficiency has not been established. ( 1 )
Mechanism: UCDs are inherited deficiencies of enzymes or transporters necessary for the synthesis of urea from ammonia (NH 3 , NH 4 + ). Absence of these enzymes or transporters results in the accumulation of toxic levels of ammonia in the blood and brain of affected patients. RAVICTI is a triglyceride containing 3 molecules of PBA. PAA, the major metabolite of PBA, is the active moiety of RAVICTI. PAA conjugates with glutamine (which contains 2 molecules of nitrogen) via acetylation in the liver and kidneys to form PAGN, which is excreted by the kidneys (Figure 1). On a molar basis, PAGN, like urea,...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 4, 2019 Supplement 11 · Efficacy LabelLetter
- Dec 21, 2018 Supplement 10 · Efficacy OrphanLabelLetter
- Apr 28, 2017 Supplement 5 · Efficacy OrphanLabelLetter
- Sep 8, 2016 Supplement 4 · Efficacy OrphanLabelLetter
- Feb 1, 2013 Original approval · Type 2 - New Active Ingredient OrphanLabelReviewLetter
1 products under this application
- RAVICTI · GLYCEROL PHENYLBUTYRATE 1.1GM/ML · LIQUID, ORAL · Prescription · TE AA
Clinical trials
Interventional ClinicalTrials.gov studies with "Glycerol Phenylbutyrate" as an intervention, any sponsor and status, largest first.
- A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic EncephalopathyPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00999167 · 189 participants · Start Dec 2009 · Primary completion Apr 2012
Drug: HPN-100; Placebo · For: Cirrhosis; Hepatic Encephalopathy
Sites: Palo Alto, California; Washington D.C., District of Columbia; Miami, Florida · 28 sites in all
AmgenAmgen (AMGN)
NCT01135680 · 98 participants · Start May 2010 · Primary completion Sep 2010
Drug: HPN-100; HPN-100 or Placebo and 4 more · For: Drug Toxicity
Sites: Madison, Wisconsin
- To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)Completed
AmgenAmgen (AMGN)
NCT01257737 · 88 participants · Start Oct 4, 2010 · Primary completion Feb 16, 2017
Drug: HPN-100 · For: Urea Cycle Disorders
Sites: Los Angeles, California; Palo Alto, California; Aurora, Colorado · 16 sites in all
- Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00947297 · 60 participants · Start Nov 2009 · Primary completion Sep 2011
Drug: HPN-100 · For: Urea Cycle Disorders
Sites: Long Beach, California; Los Angeles, California; Stanford, California · 22 sites in all
- Phenylbutyrate for Monogenetic Developmental and Epileptic EncephalopathyActive, not recruiting
Weill Medical College of Cornell UniversityAcademic, hospital or other
NCT04937062 · 50 participants (planned) · Start Mar 1, 2021 · Primary completion Dec 1, 2026
Drug: Glycerol Phenylbutyrate 1100 MG/ML [Ravicti] · For: STXBP1 Encephalopathy With Epilepsy, SLC6A1 Neurodevelopmental Disorder; Developmental and Epileptic Encephalopathy
Sites: Aurora, Colorado; New York, New York
- Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle DisordersPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00992459 · 46 participants · Start Oct 2009 · Primary completion Sep 2010
Drug: HPN-100; Buphenyl (NaPBA) · For: Urea Cycle Disorders
Sites: Long Beach, California; Los Angeles, California; Stanford, California · 22 sites in all
University of Colorado, DenverAcademic, hospital or other
NCT02046434 · 38 participants · Start Jan 2014 · Primary completion Sep 2019
Drug: Glycerol Phenylbutyrate · For: Parkinson's Disease
Sites: Aurora, Colorado
AmgenAmgen (AMGN)
NCT00986895 · 32 participants · Start Sep 2006
Drug: HPN-100 · For: Hepatic Encephalopathy; Urea Cycle Disorders
Sites: Kharkiv, Ukraine · 2 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- ammonia increased207
- vomiting168
- hyperammonaemia166
- decreased appetite106
- nausea74
- headache66
- hyperammonaemic crisis64
- off label use63
- diarrhoea58
- fatigue53
- somnolence53
- weight decreased47
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 9 |
| 2014 | 20 |
| 2015 | 270 |
| 2016 | 260 |
| 2017 | 102 |
| 2018 | 81 |
| 2019 | 96 |
| 2020 | 63 |
| 2021 | 29 |
| 2022 | 33 |
| 2023 | 106 |
| 2024 | 193 |
| 2025 | 43 |
| 2026 | 87 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Sep 1, 2026
RAVICTI, Oral Liquid, 1.1 g/1 mL (NDC 75987-050-06). Discontinuation in the manufacturing of the drug product
To Be Discontinued · updated Sep 1, 2026
RAVICTI, Oral Liquid, 1.1 g/1 mL (NDC 75987-050-07). Discontinuation in the manufacturing of the drug product
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ravicti (Glycerol Phenylbutyrate)
2024 spending
$79.5M
Beneficiaries
94
928 claims
Per beneficiary
$845,247
$222.68 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $53,970,031 |
| 2021 | $60,056,340 |
| 2022 | $66,453,447 |
| 2023 | $73,454,459 |
| 2024 | $79,453,177 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Intraindividual Comparisons to Determine Comparative Effectiveness: Their Relevance for G-BA's Health Technology Assessments.
Wagle JA, Flacke JP, Knoerzer D, et al. · Value Health 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Glutamine and hyperammonemic crises in patients with urea cycle disorders.
Lee B, Diaz GA, Rhead W, et al. · Mol Genet Metab 2016 · Clinical Trial, Research Support, N.I.H., Extramural
- Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy.
Rockey DC, Vierling JM, Mantry P, et al. · Hepatology 2014 · Clinical Trial, Phase II, Multicenter Study
- Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders.
Mokhtarani M, Diaz GA, Rhead W, et al. · Mol Genet Metab 2012 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Fasting Blood Ammonia Predicts Risk and Frequency of Hepatic Encephalopathy Episodes in Patients With Cirrhosis.
Vierling JM, Mokhtarani M, Brown RS, et al. · Clin Gastroenterol Hepatol 2016 · Clinical Trial, Phase II, Randomized Controlled Trial
- Self-reported treatment-associated symptoms among patients with urea cycle disorders participating in glycerol phenylbutyrate clinical trials.
Nagamani SC, Diaz GA, Rhead W, et al. · Mol Genet Metab 2015 · Clinical Trial, Research Support, N.I.H., Extramural
Sponsor: Amgen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.